As Ebola cases near 10,700, WHO recommends adding 2 Bundibugyo vaccines to clinical trial
Mary Van Beusekom, MSToday at 3:10 p.m.
Ebola
As the Ebola case and death total in the African outbreak continue to rise, expert groups convened by the World Health Organization (WHO) have recommended adding two candidate Bundibugyo Ebola virus vaccines to the ongoing Tumaini clinical trial.
The outbreak case total now stands at 10,699, including 5,202 deaths, the US Centers for Disease Control and Prevention reported today.
Yesterday, the UK government said that a British healthcare worker was being repatriated for medical treatment after testing positive for Ebola in outbreak epicenter, the Democratic Republic of Congo (DRC). The unidentified patient was in stable condition, The Guardian reports.
On October 3, Kenya released five Ebola patients from the hospital after tests showed they had cleared the virus, the Ministry of Health told the AP. Two patients are still receiving supportive care in the hospital.
The ministry also said 46 contacts of the country’s first Ebola patient were released after 21 days of quarantine. This follows last week’s release of 20 contacts. The 52 contacts remaining in quarantine are expected to be released next week. Kenya has reported eight cases, including two deaths, with no new cases since October 19.
Bundibugyo vaccines to be tested amid outbreak for first time
Expert groups convened by the WHO recommended adding two new Ebola vaccine candidates to the ongoing Tumaini clinical trial in the DRC, the WHO said yesterday in a news release.This will be the first time vaccines targeting the Bundibugyo Ebola virus, which is causing the current outbreak, will be tested during an outbreak of the strain.
Vaccines alone will not end this outbreak, but they could become a powerful new tool for bringing it under control.
Tedros Adhanom Ghebreyesus, PhD
The vaccine candidates are ChAdOx1, developed by the University of Oxford and the Serum Institute of India, and Moderna’s mRNA-1469. They will enter the trial after national approvals. “Vaccines alone will not end this outbreak, but they could become a powerful new tool for bringing it under control,” WHO Director-General Tedros Adhanom Ghebreyesus, PhD, said in the release.
Tumaini was designed to test multiple vaccine candidates within a single trial using a ring-vaccination approach that enrolls contacts of infected people. Ervebo, a vaccine used against the Zaire Ebola virus, is the first vaccine being evaluated to assess efficacy against the Bundibugyo virus.
Research into potential treatments is also progressing, the WHO said. The WHO-sponsored PARTNERS trial is assessing whether the monoclonal antibody MBP134, the antiviral drug remdesivir, or a combination of both can boost survival among Bundibugyo patients.
The monoclonal antibody maftivimab will soon be added to the trial as a potential treatment. A complementary post-exposure prophylaxis study with the antiviral medication obeldevisir is already under way.